On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health.
Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Webinar: Implications of the IRA for Biotech Companies
This webinar will focus on the implications of the Inflation Reduction Act (IRA) on value proposition development and the evidence needed for drugs launching in 2027-2028 that plan to seek reimbursement from Medicare. Join PRECISIONvalue’s Andrew Cournoyer and Precision Value & Health’s Ross Maclean for this value packed webinar.
Access90: Inflation Reduction Act Insight Series – Rebates and WAC: Two Key Questions Answered
The Inflation Reduction Act will definitely impact established wholesale acquisition costs and rebates. Now that the Medicare bid season is upon us, how can manufacturers prepare? PRECISIONvalue expert Andrew Cournoyer, SVP of the Access Experience Team, explains in this must-see video.
PRECISIONadvisors New Office Opening in London
The PRECISIONadvisors team is looking forward to welcoming clients and Precision colleagues to their new office opening this week. The client networking event includes a panel discussion on the evolving marketing access environment in the UK featuring Andrew Walker, David Watson and Neil Grubert. Reach out to Richard Macaulay to attend!
Access90: Inflation Reduction Act Insight Series – Rebates and WAC: A Key Question Answered
When you squeeze a balloon, the air goes somewhere. Same with the cost of drugs. PRECISIONvalue expert Andrew Cournoyer, SVP of the Access Experience Team, explains the anticipated fallout from the Inflation Reduction Act in this 90-second video.
Access90: Inflation Reduction Act Insight Series – Biosimilars: A Key Question Answered (Part 2)
Biosimilars deliver dramatic reductions in drug costs—and the Inflation Reduction Act is supposed to encourage their uptake. But lower prices mean lower reimbursement, disincentivizing providers. PRECISIONvalue expert Amy Martin explains how in this 2-minute video.
Access90: Inflation Reduction Act Insight Series – Biosimilars: A Key Question Answered (Part 1)
How will the Inflation Reduction Act effect manufacturers of both originator drugs and biosimilars? According to PRECISIONvalue expert Amy Martin, a range of unintended consequences may impact pricing, innovation—and ultimately the therapies available to patients. Watch this short video to see why.
PRECISION is named a RECOGNIZED INNOVATOR twice in PM360 Magazine’s 2023 Innovators Issue
PRECISION is named a RECOGNIZED INNOVATOR twice in PM360 Magazine’s 2023 Innovators Issue for our Access Genius Insights and Navigator365 Core and Cx Benchmark technologies.
Access Genius combines best-in-class technology and unmatched data synthesis in a smart pharmaceutical market access messaging platform.
The Navigator365 suite of HCP insight products provide the tools and evidence clients need to answer key business questions and deliver a signature brand experience for their customers and patients.
Read more about how these innovative technologies in PM360’s Innovators Issue HERE.
Precision Medicine Group Releases Its Inaugural Environmental, Social and Governance (ESG) Report
Precision is proud to have published our inaugural 2023 Environmental, Social and Governance (ESG) Report, reflecting the company’s ongoing efforts to do better for our people, in our practices, and with the broader community at large. This year’s report shares key achievements, performance metrics, and steps we have taken to enhance sustainability throughout the company, including:
· Engaging internal and external stakeholders in our company’s first ESG materiality assessment to identify and prioritize our material issues
· Defining Precision’s approach to ESG in our company’s ESG Strategy Statement · Creating a three-year strategic ESG Roadmap for advancing our performance across environmental, social, and governance issues · Initiating energy efficiency projects and standards across our facilities
· Implementing implicit bias training for our Executive Leadership Team and Human Resources leaders
· Contributing volunteer hours by over 425 employees and over $250,000 in donations to more than 70 charitable foundations and causes
Article: Anshul Mangal of Project Farma Discusses Policy Strategies to Address the Current Cancer Drug Shortage
In September, the American Association for Cancer Research reported that hospitals are facing the worst chemotherapy drug shortage crisis the US has ever seen. Anshul Mangal, President of Project Farma, sat down with AJMC to address the primary reasons for the current cancer drug shortages and how Project Farma is helping to address these challenges.